AstraZeneca: licensing agreement finalised for CMG901
(CercleFinance.com) - AstraZeneca announced on Thursday that it had finalised its licensing agreement with KYM Biosciences for CMG901, an antibody-drug conjugate considered promising for the treatment of gastric cancer.
The biopharmaceutical group points out that the molecule is currently undergoing phase 1 trials in the treatment of solid tumours expressing claudin 18.2, in particular gastric cancer.
The company says that the preliminary results of the study showed an "encouraging" profile, with evidence of anti-tumour activity at all prescribed doses.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The biopharmaceutical group points out that the molecule is currently undergoing phase 1 trials in the treatment of solid tumours expressing claudin 18.2, in particular gastric cancer.
The company says that the preliminary results of the study showed an "encouraging" profile, with evidence of anti-tumour activity at all prescribed doses.
Copyright (c) 2023 CercleFinance.com. All rights reserved.